Statin intolerance – a question of definition

References

• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
   PubMed Web of Science ®Google Scholar
• Miller PE, Martin SS. Approach to statin use in 2016: an update. Curr Atheroscler Rep. 2016;18:20.
   PubMed Web of Science ®Google Scholar
• Mihos CG, Pineda AM, Santana O. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res. 2014;88:12–19.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al.; Authors/Task Force M, Additional C. 2016 ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016. pii: ehw272. doi:10.1093/eurheartj/ehw272. [Epub ahead of print]
   Web of Science ®Google Scholar
• Jacobson TA. NLA task force on statin safety–2014 update. J Clin Lipidol. 2014;8:S1–S4.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Macchi C, Morlotti B, et al. Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med. 2014;25:401–406.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Expert Opin Drug Saf. 2015;14:935–955.
   PubMed Web of Science ®Google Scholar
• Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2:205–207.
   PubMedGoogle Scholar
• Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol. 2013;29:1553–1568.
   PubMed Web of Science ®Google Scholar
• Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526–534.
   PubMed Web of Science ®Google Scholar
• Kim MC, Cho JY, Jeong HC, et al. Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction. Am J Cardiol. 2015;115:1–7.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781–1790.
   PubMed Web of Science ®Google Scholar
• Hovingh GK, Gandra SR, McKendrick J, et al. Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. Atherosclerosis. 2016;245:111–117.
   PubMed Web of Science ®Google Scholar
• Fung EC, Crook MA. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc Ther. 2012;30:e212–e218.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68:92–125.
   Google Scholar
• ACC’s statin intolerance tool: American college of cardiology. [cited2016 Sep 14]. Available from: http://tools.acc.org/StatinIntolerance/
   Google Scholar
• Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab Syndr Obes Target Ther. 2011;4:155–166.
   PubMedGoogle Scholar
• Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother. 2013;47:398–404.
   PubMed Web of Science ®Google Scholar
• Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265:568–580.
   PubMed Web of Science ®Google Scholar
• Zetia ® summary of product information 08/2013. [cited 2016 Sep 13]. Available from: https://www.merck.com/product/usa/pi_circulars/z/zetia/zetia_pi.pdf
   Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Burke FM. Red yeast rice for the treatment of dyslipidemia. Curr Atheroscler Rep. 2015;17:495.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gutierrez R, Shah ND, Montori VM. Predicting the overuse of PCSK-9 inhibitors. JAMA. 2015;314:1909–1910.
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Gidding SS. PCSK9 inhibitors: a technology worth paying for? Pharmacoeconomics. 2016;34:217–220.
   PubMed Web of Science ®Google Scholar
• Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10:373–387.
   PubMed Web of Science ®Google Scholar
• Laufs U, Scharnagl H, März W. Statin intolerance. Curr Opin Lipidol. 2015;26:492–501.
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83:687–700.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S58–S71.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681–1690.
   PubMed Web of Science ®Google Scholar
• Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014;96:470–476.
   PubMed Web of Science ®Google Scholar
• Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33:171–187.
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 2008;359:789–799.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Johnson SG, Caudle KE, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96:423–428.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109:III50–III57.
   PubMed Web of Science ®Google Scholar
• Rowan CG, Brunelli SM, Munson J, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012;21:494–506.
   PubMed Web of Science ®Google Scholar
• Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21:464–474.
   PubMed Web of Science ®Google Scholar
• Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016;37:908–916.
   Web of Science ®Google Scholar
• Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497–2506.
   PubMed Web of Science ®Google Scholar
• Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541–2548.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580–1590.
   Web of Science ®Google Scholar
• Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8:554–561.
   PubMed Web of Science ®Google Scholar
• Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33:1142–1149.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9:295–304.
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Doney AS, Tavendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 2011;89:210–216.
   PubMed Web of Science ®Google Scholar
• Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis. 2007;6:7.
   PubMed Web of Science ®Google Scholar
• Di Pierro F, Bellone I, Rapacioli G, et al. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diab Metab Syndr Obes Target Ther. 2015;8:89–96. Epub 2015/02/14.
   PubMed Web of Science ®Google Scholar
• Degreef LE, Opdam FL, Teepe-Twiss IM, et al. The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. Eur J Intern Med. 2010;21:293–296.
   PubMed Web of Science ®Google Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, et al. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007;23:2183–2192.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Abuchaibe C, Wang P. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med Hypotheses. 2011;77:658–661.
   PubMed Web of Science ®Google Scholar
• Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105:198–204.
   PubMed Web of Science ®Google Scholar
• Kennedy SP, Barnas GP, Schmidt MJ, et al. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol. 2011;5:308–315.
   PubMed Web of Science ®Google Scholar
• Harris LJ, Thapa R, Brown M, et al. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. J Clin Lipidol. 2011;5:299–307.
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Pazzucconi F, Colombo L, et al. Double-blind study of the addition of high-protein soya milk v. cows’ milk to the diet of patients with severe hypercholesterolaemia and resistance to or intolerance of statins. Br J Nutr. 1999;82:91–96.
   PubMed Web of Science ®Google Scholar
• Khayznikov M, Hemachrandra K, Pandit R, et al. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci. 2015;7:86–93.
   PubMed Web of Science ®Google Scholar
• Becker DJ, French B, Morris PB, et al. Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial. Am Heart J. 2013;166:187–196.
   PubMed Web of Science ®Google Scholar
• Goldberg AS, DeGorter MK, Ban MR, et al. Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. Can J Cardiol. 2013;29:915–919.
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke. 2002;33:2337–2341.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med. 2014;160:339–343.
   PubMed Web of Science ®Google Scholar
• Guyton JR, Bays HE, Grundy SM, et al. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8:S72–S81.
   PubMed Web of Science ®Google Scholar
• [ cited 2015 Dec]. Available from: http://apps.who.int/classifications/icd10/browse/2016/en.
   Google Scholar
• Kopecky S, Baum S, Foody JM, et al. Insights into statin intolerance. Clin Cardiol. 2015;38:520–526.
   PubMed Web of Science ®Google Scholar
• Keen HI, Krishnarajah J, Bates TR, et al. Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? Expert Opin Drug Saf. 2014;13:1227–1239.
   PubMed Web of Science ®Google Scholar
• Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011;365:2250–2251.
   PubMed Web of Science ®Google Scholar
• Raju SB, Varghese K, Madhu K. Management of statin intolerance. Indian J Endocrinol Metab. 2013;17:977–982.
   PubMedGoogle Scholar
• Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597–603.
   PubMed Web of Science ®Google Scholar
• Joy TR, Zou GY, Mahon JL. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;161:531–532.
   PubMed Web of Science ®Google Scholar